Si Xiaoyan, Wu Shafei, Feng Rui'e, Wang Xuan, Guan Hui, He Jia, Zeng Xuan, Song Wei, Li Shanqing, Hu Ke, Liang Zhiyong, Zhang Fuquan, Huo Li, Cheng Xin, Zhuo Minglei, Liu Wei, Liu Yong, Zhou Xi, Wang Tao, Zhang Yuhui, Ni Jun, Wang Xiaojun, Zhao Jing, Xu Yan, Zhang Xiaotong, Wang Hanping, Liu Xiaoyan, Wang Mengzhao, Cui Xiaoxia, Zhang Li, Xu Kaifeng
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Thorac Cancer. 2025 Mar;16(5):e70027. doi: 10.1111/1759-7714.70027.
Inflammatory myofibroblastic tumor (IMT) is a rare spindle-cell neoplasm. IMT currently suffers from a paucity of standardized diagnostic and therapeutic guidelines. The Chinese expert consensus committee on the diagnosis and treatment of IMT formed an "Expert consensus on the diagnosis and treatment of inflammatory myofibroblastic tumor". This consensus was developed through a comprehensive synthesis of expert opinions, an extensive review of the literature, and a series of offline and online deliberations. The committee aspires that this consensus will enhance the therapeutic outcomes and prognosis for patients with IMT in the future.
炎性肌纤维母细胞瘤(IMT)是一种罕见的梭形细胞肿瘤。目前,IMT缺乏标准化的诊断和治疗指南。中国炎性肌纤维母细胞瘤诊断与治疗专家共识委员会形成了《炎性肌纤维母细胞瘤诊断与治疗专家共识》。该共识是通过综合专家意见、广泛查阅文献以及一系列线下和线上讨论而制定的。委员会期望这一共识在未来能改善IMT患者的治疗效果和预后。